<DOC>
	<DOCNO>NCT01855087</DOCNO>
	<brief_summary>There paucity information combination therapy dipeptidyl peptidase-4 inhibitor sitagliptin insulin . This study aim retrospectively investigate safety efficacy therapeutic modality Japanese patient type 2 diabetes .</brief_summary>
	<brief_title>Safety Efficacy Sitagliptin Added Insulin Therapy Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>outpatient type 2 diabetes addition sitagliptin insulin therapy age 20 year old HbA1c 6.9 % high ( NGSP ) time add sitagliptin history hypersensitivity sitagliptin severe ketosis , diabetic coma , and/or precoma within 6 month sitagliptin administration sever infection and/or severe trauma , and/or patient schedule undergo / recently undergo surgery severe renal dysfunction ( serum creatinine [ mg/dL ] : 2.5 high men ; 2.0 high woman ) ongoing treatment glinide ( ) judgment ineligible study attend physician</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>